942999-08-8

Upstream product

• 942999-56-6 N-(tert-butyloxycarbonyl)-3,5-di-(isopropoxy)aniline 
• 150242-82-3 3,5-di-(isopropyloxy)benzoic acid 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 94169-62-7 methyl 3,5-di-isopropoxybenzoate 

Downstream Products

• 1006584-05-9 C₂₈H₄₀N₂O₆ 
• 1032435-05-4 N-[(3,5-diisopropoxy)phenyl] 4-[(2-amino)ethoxy]-3,5-dimethylbenzamide hydrochloride 

Relevant academic research and scientific papers

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator

Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided

THERAPEUTIC COMPOUNDS

This invention relates to a novel class of substituted amino-ethoxy benzene derivatives of formula (I) which are inhibitors of serine proteases and to their use in treating aberrant serine protease activity in a mammal, contraception, anti-coagulant methods and methods for treating aberrant cell proliferation, tumours, cancer, angiogenesis, angiogenesis-based retinopathies, autoimmummune disease, inflammation, skin disease, arthritis, rheutmatoid arthritis, asthma, osteoarthritis and multiple sclerosis. (I), Wherein Rm, Rn, Rp, Rq, V, W, X, Y and R8 are as defined in the claims.